Mathilde Marchand
Overview
Explore the profile of Mathilde Marchand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chan P, Liu S, Gosselin N, Sauve Z, Marchand M, Lin A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2025 Feb;
PMID: 39906948
IMscin001 is a two-part dose-finding (Phase Ib) and -confirmation (Phase III) study to evaluate atezolizumab pharmacokinetics of subcutaneous (SC) compared with intravenous (IV) administration in patients with locally advanced or...
2.
Bender B, Li C, Marchand M, Turner D, Li F, Vadhavkar S, et al.
Clin Transl Sci
. 2024 May;
17(6):e13825.
PMID: 38808543
Mosunetuzumab (Mosun) is a CD20xCD3 T-cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. The approved step-up dose regimen of 1/2/60/30 mg IV is designed to...
3.
Marchand M, Goncalves A, Mercier F, Chanu P, Jin J, Guedj J, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Apr;
13(6):1017-1028.
PMID: 38629452
Model-based tumor growth inhibition (TGI) metrics are increasingly used to predict overall survival (OS) data in Phase III immunotherapy clinical trials. However, there is still a lack of understanding regarding...
4.
Goncalves A, Marchand M, Chan P, Jin J, Guedj J, Bruno R
CPT Pharmacometrics Syst Pharmacol
. 2023 Oct;
13(1):68-78.
PMID: 37877248
Two-stage and joint modeling approaches are the two main approaches to investigate the link between longitudinal tumor size data and overall survival (OS) and anticipate clinical trial outcome. We here...
5.
Bruno R, Marchand M, Yoshida K, Chan P, Li H, Zou W, et al.
Clin Cancer Res
. 2023 Oct;
29(20):4314.
PMID: 37828897
No abstract available.
6.
Shemesh C, Chan P, Marchand M, Goncalves A, Vadhavkar S, Wu B, et al.
Clin Pharmacol Ther
. 2023 May;
114(3):644-651.
PMID: 37212707
We assess the longitudinal tumor growth inhibition (TGI) metrics and overall survival (OS) predictions applied to patients with advanced biliary tract cancer (BTC) enrolled in IMbrave151 a multicenter randomized phase...
7.
Bruno R, Marchand M, Yoshida K, Chan P, Li H, Zou W, et al.
Clin Cancer Res
. 2023 Jan;
29(6):1047-1055.
PMID: 36595566
Purpose: Model-based tumor growth inhibition (TGI) metrics are increasingly incorporated into go/no-go decisions in early clinical studies. To apply this methodology to new investigational combinations requires independent evaluation of TGI...
8.
Liu S, Marchand M, Liu X, Ingle G, Maiya V, Graupner V, et al.
J Clin Pharmacol
. 2022 May;
62(11):1393-1402.
PMID: 35576521
Atezolizumab is approved as an intravenous (IV) infusion for use as a single agent and in combination with other therapies in a number of indications. The objectives of this publication...
9.
Yoshida K, Chan P, Marchand M, Zhang R, Wu B, Ballinger M, et al.
AAPS J
. 2022 Apr;
24(3):58.
PMID: 35484442
Longitudinal changes of tumor size or tumor-associated biomarkers have been receiving growing attention as early markers of treatment benefits. Tumor growth inhibition-overall survival (TGI-OS) models represent mathematical frameworks used to...
10.
Chan P, Marchand M, Yoshida K, Vadhavkar S, Wang N, Lin A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Jul;
10(10):1171-1182.
PMID: 34270868
The objectives of the study were to use tumor size data from 10 phase II/III atezolizumab studies across five solid tumor types to estimate tumor growth inhibition (TGI) metrics and...